| Publications by Biophoenix' Principals |
| European Market for Drug Delivery Systems | |
|---|---|
 | |
| Publisher: | Frost & Sullivan Inc |
| Year of publication: | 1994 |
| Type of publication: | Market report |
| Publisher's reference (if any): | E1860 |
| Author(s): | Sreten Bogdanovic and Beata Langlands |
| Approximate page count: | 300 |
| Price when published: | $3,400 |
Remarks:
| |
EUROPEAN MARKET FOR DRUG
DELIVERY SYSTEMS
FROST & SULLIVAN (1994)
(E1860)
CONTENTS
Page
TABLE OF CONTENTS TOC.1
LIST OF TABLES TOC.7
EXECUTIVE SUMMARY ES.1
CHAPTER 1 INTRODUCTION, SCOPE, METHODOLOGY,
AND DEFINITIONS
1. INTRODUCTION 1.1
2. OBJECTIVES AND SCOPE OF THIS REPORT 1.5
2.1 Major objectives 1.5
2.2 Scope of this report 1.6
3. METHODOLOGY 1.9
4. ABBREVIATIONS AND DEFINITIONS 1.11
5. OUTLINE OF THE REPORT 1.13
6. CURRENCY EXCHANGE RATES 1.21
CHAPTER 2 TECHNOLOGY AND MARKET NEEDS
1. INTRODUCTION 2.1
2. TERMS USED IN PHARMACOKINETICS 2.2
3. MATERIALS USED IN DRUG DELIVERY SYSTEMS 2.4
3.1 Polymers 2.4
3.1.1 Introduction 2.4
3.1.2 Soluble synthetic polymers 2.5
3.1.3 Biodegradable polymers 2.5
3.1.4 Mucoadhesive polymers 2.6
3.2 Colloidal particles 2.6
3.3 Prodrugs 2.9
4. ORAL DRUG DELIVERY 2.9
4.1 Introduction 2.9
4.2 Mechanisms of controlled-release
from oral dosage forms 2.10
4.2.1 Dissolution control 2.11
4.2.2 Diffusion control 2.11
4.2.3 Osmotic control 2.12
4.2.4 Chemical control 2.15
4.3 Controlled-release oral delivery systems 2.15
4.4 Patented oral drug delivery systems 2.18
4.5 Therapeutic applications 2.23
5. TRANSDERMAL DRUG DELIVERY 2.25
5.1 Introduction 2.25
5.2 Technologies for transdermal drug delivery 2.27
5.2.1 Multilaminate adhesive dispersion 2.27
5.2.2 Matrix diffusion 2.27
5.2.3 Membrane permeation 2.28
5.3 Enhancement of percutaneous absorption 2.29
5.4 Therapeutic applications 2.29
5.5 Electrically-aided transdermal delivery 2.31
5.5.1 Introduction 2.31
5.5.2 Iontophoresis 2.32
5.5.3 Electroporation 2.32
5.5.4 Panoderm system 2.33
5.5.5 Therapeutic applications 2.33
6. PARENTERAL DRUG DELIVERY 2.34
6.1 Implantable venous access devices,
lightweight pumps and auto-injectors 2.34
6.1.1 Therapeutic applications 2.35
6.2 Implants 2.36
6.2.1 Introduction 2.36
6.2.2 Implantable pumps 2.37
6.2.3 Nondegradable polymeric inserts 2.39
6.2.4 Biodegradable polymeric inserts 2.39
6.2.5 Membrane-adhesive inserts 2.40
6.2.6 Therapeutic applications of implants 2.41
7. CARRIER-ASSISTED DRUG DELIVERY 2.43
7.1 Liposomes 2.43
7.2 Low-density lipoproteins (LDLs) 2.45
7.3 Zynaxis' Zyn-linker molecules 2.46
7.4 Partisomes (magnetic particles) 2.46
7.5 Monoclonal antibodies 2.46
7.6 Therapeutic applications 2.47
8. TOPICAL DRUG DELIVERY 2.49
8.1 Photodynamic therapy 2.49
8.2 Hyaluronic acid technology 2.50
8.3 Hydron technology 2.50
9. PULMONARY AND INTRANASAL DRUG DELIVERY 2.51
9.1 Introduction 2.51
9.2 Pulmonary drug delivery 2.51
9.2.1 Dry powder inhalers 2.51
9.2.2 Prolonged-release formulations 2.51
9.3 Intranasal drug delivery 2.52
9.4 Therapeutic applications 2.53
10. DRUG DELIVERY TO THE BRAIN AND THE EYE 2.53
10.1 Drug delivery to the brain 2.53
10.1.1 Modifying the blood-brain barrier 2.53
10.1.2 Modifying the drugs for brain delivery 2.54
10.1.3 Circumventing the blood-brain barrier 2.54
10.2 Drug delivery to the eye 2.55
11. OTHER DRUG DELIVERY ROUTES 2.56
11.1 Buccal drug delivery 2.56
11.2 Rectal drug delivery 2.56
12. DELIVERY OF BIOPHARMACEUTICALS 2.57
12.1 Introduction 2.57
12.2 Intranasal delivery 2.60
12.3 Parenteral delivery 2.61
12.4 Pulmonary delivery 2.62
CHAPTER 3 PRODUCTS AND MARKET SATISFACTION
1. INTRODUCTION 3.1
2. ORAL PRODUCTS 3.2
2.1 Launched products on the European market 3.2
2.2 Anticipated product launches in Europe 3.2
2.3 Performance of launched products 3.2
2.4 Products in clinical trials 3.7
3. TRANSDERMAL PATCHES 3.7
3.1 Transdermal patches on the market 3.7
3.3 Performance of launched transdermal patches 3.12
3.4 Transdermal patches in development 3.14
4. ELECTRICALLY-AIDED TRANSDERMAL DELIVERY PRODUCTS 3.14
4.1 Devices recently launched 3.14
4.2 Devices in development 3.14
5. VENOUS ACCESS DEVICES 3.20
5.1 Products launched or awaiting launch 3.20
5.2 Performance of launched products 3.20
5.3 Products in development 3.20
6. LIGHTWEIGHT PUMPS 3.20
6.1 Recently launched products 3.20
6.3 Performance of launched products 3.20
7. AUTOINJECTORS AND INJECTION PENS 3.21
7.1 Products on the market and in development 3.21
7.2 Performance of launched products 3.21
8. IMPLANTABLE PUMPS 3.21
8.1 Recent launches 3.32
8.2 Performance of launched products 3.32
8.3 Products in development 3.32
9. NONDEGRADABLE IMPLANTS 3.32
9.1 Products on the market 3.32
9.2 Performance of launched products 3.33
9.3 Products in development 3.33
10. BIODEGRADABLE IMPLANTS 3.33
11. MUCOADHESIVE IMPLANTS 3.34
12. LIPOSOMES 3.34
12.1 Liposomal products on the market 3.34
12.2 Performance of launched products 3.34
12.3 Liposomal products in development 3.35
12.4 Performance of liposomal products
in clinical trials 3.35
13. OTHER DRUG CARRIER PRODUCTS 3.40
14. TOPICAL PRODUCTS 3.40
14.1 Photodynamic therapy products 3.40
14.2 Hyaluronic acid products 3.41
14.3 Hydron technology 3.41
15. PULMONARY PRODUCTS 3.41
15.1 Devices for use with metered-dose inhalers 3.41
15.1.1 Recently launched products 3.41
15.1.2 Products in development 3.42
15.2 Dry powder inhalers 3.42
16. INTRANASAL PRODUCTS 3.42
17. BRAIN DRUG DELIVERY PRODUCTS 3.42
18. EYE PRODUCTS 3.43
18.1 Products on the market 3.43
18.2 Products in development 3.43
18.2.1 Implants 3.43
18.2.2 Eyedrop formulations 3.44
19. BUCCAL PRODUCTS 3.44
20. DELIVERY OF BIOPHARMACEUTICALS 3.45
20.1 Available products 3.45
20.2 Products in development 3.46
CHAPTER 4 THE MARKET - ANALYSES AND GROWTH FORECASTS
1. INTRODUCTION 4.1
2. OVERVIEW OF EUROPEAN HEALTHCARE SYSTEMS 4.1
3. REVIEW OF NATIONAL MARKETS 4.2
3.1 Belgium 4.2
3.2 France 4.3
3.3 Germany 4.3
3.4 Italy 4.4
3.5 The Netherlands 4.5
3.6 Spain 4.7
3.7 United Kingdom 4.8
4. DEMOGRAPHIC SUMMARY 4.10
5. PHARMACEUTICAL PRICING ISSUES 4.12
6. PHARMACEUTICAL DISTRIBUTION 4.14
7. DRUG DEVELOPMENT ISSUES 4.16
8. PATENT TERM AND GENERIC COMPETITION ISSUES 4.19
9. OVERVIEW OF EUROPEAN DRUG REGULATION 4.21
10. MARKET ANALYSIS AND FORECASTS 4.23
10.1 Introduction 4.23
10.2 Cardiovascular drugs 4.27
10.3 Respiratory drugs 4.29
10.4 Musculoskeletal drugs 4.30
10.5 Drugs acting on the central
nervous system (CNS) 4.30
10.6 Hormones and endocrinology 4.32
10.7 Cancer therapy 4.36
10.9 Analgesia 4.37
10.10 Anti-infective agents 4.38
10.11 Other therapeutic applications 4.40
10.12 Smoking cessation 4.41
10.13 DDS product groups 4.43
10.14 National markets 4.46
CHAPTER 5 COMPANY PROFILES
1. Introduction 5.1
2. Affinity Biotech Incorporated 5.14
3. Alza Corporation 5.19
3.1 Parent company 5.19
3.2 Therapeutic Discovery Corporation 5.25
4. Bioject Medical Technologies Incorporated 5.27
5. Cortecs International Limited 5.30
6. Cygnus Therapeutic Systems Incorporated 5.32
7. CytoTherapeutics Incorporated 5.39
8. Elan Pharmaceutical Limited 5.44
9. Ethical Holdings PLC 5.49
10. Hyal Pharmaceutical Corporation 5.53
11. I-Flow Corporation 5.58
12. Liposome Technology Incorporated 5.59
13. The Liposome Company Incorporated 5.65
14. MacroChem Corporation 5.71
15. Matrix Pharmaceutical Incoporated 5.73
16. Noven Pharmaceuticals Incorporated 5.81
17. Pharmos Corporation 5.84
18. Survival Technology Incorporated 5.90
19. TheraTech Incorporated 5.96
20. Vestar Incorporated 5.102
CHAPTER 6 TRENDS AND OPPORTUNITIES
1. INTRODUCTION 6.1
2. TECHNOLOGY TRENDS 6.1
2.1 Oral Drug Delivery 6.1
2.1.1 Multi-particulate systems 6.1
2.1.2 Targeted and pulsatile delivery 6.2
2.2 Transdermal drug delivery 6.2
2.2.1 Improved passive diffusional systems 6.2
2.2.2 Triggered and pulsatile delivery 6.3
2.3 Implantable pumps 6.3
2.4 Biodegradable and biocompatible implants 6.3
2.3.1 Triggered and pusatile drug delivery 6.3
2.5 Cellular implants 6.4
2.6 Novel drug carriers 6.5
2.7 Hydrogels in topical delivery 6.6
2.8 Sustained pulmonary delivery 6.6
2.9 Delivery of biopharmaceuticals 6.6
2.9.1 Oral delivery 6.6
2.9.1.1 Targeting to the colon 6.6
2.9.1.2 Proteinoids 6.7
2.9.1.3 Microemulsion technology 6.7
2.9.1.4 pH-sensitive hydrogel 6.8
2.9.1.5 Lipid prodrugs 6.8
2.9.2 Controlled-release injectables
and implants 6.8
2.9.2.1 Novel polymers 6.8
2.9.2.2 Ceramic nanoparticles 6.8
2.9.3 Transdermal delivery 6.9
2.9.4 Ocular delivery 6.9
2.9.5 Peptide drug delivery to the brain 6.9
2.10 Gene Therapy 6.10
2.10.1 Introduction 6.10
2.10.2 Technologies for gene delivery 6.11
2.10.2.1 Retroviral vectors 6.11
2.10.2.2 Adenoviruses 6.11
2.10.2.3 Liposomes 6.12
2.10.2.4 Other chemical carriers 6.12
3. PRODUCT TRENDS 6.12
3.1 Oral products 6.12
3.2 Transdermal products 6.13
3.3 Implants 6.13
3.3.1 Implants for pulsatile delivery 6.13
3.3.2 Novel products 6.13
3.3.3 Cellular implant products 6.14
3.4 Novel liposomal products 6.14
3.5 Other drug carrier products 6.15
3.6 Topical products 6.16
3.8 Products for delivery of biopharmaceuticals 6.16
3.9 Gene Therapy 6.16
4. CURRENT AND FUTURE MARKET TRENDS 6.17
4.1 Market for oral controlled-release products 6.17
4.2 Market for transdermal products 6.23
4.3 Market for ambulatory and disposable pumps 6.24
4.4 Market for autoinjectors 6.24
4.5 Market for implantable pumps and
polymeric implants 6.24
4.6 Market for liposomes 6.25
4.7 Market for LDL products 6.25
4.8 Market for biopharmaceutical delivery systems 6.26
4.9 Market for gene therapy delivery systems 6.26
5. CURRENT AND EMERGING OPPORTUNITIES 6.26
5.1 Current opportunities 6.26
5.1.1 Oral delivery 6.26
5.1.2 Transdermal delivery 6.26
5.1.3 Home therapy market 6.28
5.1.4 Implants 6.28
5.1.5 Liposomes 6.28
5.2 Future opportunities 6.28
5.2.1 Biopharmaceutical delivery 6.28
5.2.2 Delivery vehicles for gene therapy 6.29
APPENDIX 1 COMPANY DIRECTORY A1.1
APPENDIX 2 TRADE SHOWS AND MEETINGS A2.1
APPENDIX 3 COMPANY INDEX A3.1
LIST OF TABLES
TABLE 1.1 EXCHANGE RATES USED IN THIS REPORT 1.22
TABLE 3.1 CURRENTLY AVAILABLE ORAL
CONTROLLED-RELEASE PRODUCTS 3.4
TABLE 3.2 ORAL CONTROLLED-RELEASE PRODUCTS
AWAITING LAUNCH 3.8
TABLE 3.3 ORAL CONTROLLED-RELEASE PRODUCTS
IN CLINICAL TRIALS 3.9
TABLE 3.4 TRANSDERMAL CONTROLLED-RELEASE
PRODUCTS ON THE MARKET 3.10
TABLE 3.5 TRANSDERMAL CONTROLLED-RELEASE
PRODUCTS IN DEVELOPMENT 3.15
TABLE 3.6 ELECTROTRANSPORT PRODUCTS
IN DEVELOPMENT 3.22
TABLE 3.7 VENOUS ACCESS DEVICES LAUNCHED
OR AWAITING LAUNCH 3.24
TABLE 3.8 VENOUS ACCESS DEVICES IN DEVELOPMENT 3.25
TABLE 3.9 LAUNCHED AMBULATORY AND DISPOSABLE PUMPS 3.26
TABLE 3.10 AUTOINJECTORS AND INJECTION PENS 3.29
TABLE 3.11 BIODEGRADABLE AND MUCOADHESIVE
IMPLANTS IN DEVELOPMENT 3.36
TABLE 3.12 LIPOSOMES AND RELATED PRODUCTS 3.38
TABLE 4.1 GENERAL DATA ON THE COUNTRIES
SURVEYED IN THIS REPORT 4.11
TABLE 4.2 COSTS OF DEVELOPING A NEW DRUG 4.17
TABLE 4.3 EC CONCERTATION (BIO-/HIGH-TECH)
APPROVALS PROCEDURE 4.26
TABLE 4.4 EUROPEAN PHARMACEUTICAL MARKET
BY THERAPEUTIC CLASS, 1992 4.47
TABLE 4.5 EUROPEAN PHARMACEUTICAL MARKET
IN 1992 AND 1998 4.49
TABLE 4.6 EUROPEAN ANTI-HYPERTENSIVE DDS
MARKET BY REGION, 1992-1998 4.50
TABLE 4.7 EUROPEAN `OTHER CARDIOVACULAR'
DDS MARKET BY REGION, 1992-1998 4.50
TABLE 4.8 EUROPEAN RESPIRATORY DDS MARKET
BY REGION, 1992-1998 4.51
TABLE 4.9 EUROPEAN MUSCULOSKELETAL DDS
MARKET BY REGION, 1992-1998 4.51
TABLE 4.10 EUROPEAN CNS DDS MARKET
BY REGION, 1992-1998 4.52
TABLE 4.11 EUROPEAN POSTMENOPAUSAL HRT
DDS MARKET BY REGION, 1992-1998 4.52
TABLE 4.12 EUROPEAN `OTHER ENDOCRINE' DDS
MARKET BY REGION, 1992-1998 4.53
TABLE 4.13 EUROPEAN CANCER DDS MARKET
BY REGION, 1992-1998 4.53
TABLE 4.14 EUROPEAN ANALGESIA DDS MARKET
BY REGION, 1992-1998 4.54
TABLE 4.15 EUROPEAN ANTIBIOTIC, -FUNGAL, &
-VIRAL DDS MARKET BY REGION, 1992-1998 4.54
TABLE 4.16 EUROPEAN `OTHER' DDS MARKET
BY REGION, 1992-1998 4.55
TABLE 4.17 EUROPEAN PATCH SMOKING CESSATION
MARKET BY REGION, 1992-1998 4.55
TABLE 4.18 EUROPEAN ORAL DDS MARKET
BY REGION, 1992-1998 4.56
TABLE 4.19 EUROPEAN TRANSDERMAL DDS MARKET
BY REGION, 1992-1998 4.56
TABLE 4.20 EUROPEAN PARENTERAL DDS MARKET
BY REGION, 1992-1998 4.57
TABLE 4.21 EUROPEAN LIPOSOME DDS MARKET
BY REGION, 1992-1998 4.57
TABLE 4.22 EUROPEAN `OTHER TECHNOLOGY'
DDS MARKET BY REGION, 1992-1998 4.58
TABLE 4.23 SUMMARY OF DDS MARKET BY COUNTRY
IN 1992 AND 1998 4.58
TABLE 4.24 SUMMARY OF DDS MARKET BY APPLICATION
IN 1992 AND 1998 4.59
TABLE 4.25 SUMMARY OF DDS MARKET BY PRODUCT GROUP
IN 1992 AND 1998 4.59
TABLE 4.26 SUMMARY OF 1992 DDS MARKET BY APPLICATION,
PRODUCT GROUP, AND COUNTRY 4.60
TABLE 4.27 SUMMARY OF 1998 DDS MARKET BY APPLICATION,
PRODUCT GROUP, AND COUNTRY 4.61
TABLE 5.1 MAJOR DDS COMPANIES: SUMMARY OF
TECHNOLOGY AND BUSINESS ACTIVITIES 5.5
TABLE 5.2 TOP 20 PHARMACEUTICAL COMPANIES IN 1992 5.12
TABLE 5.3 THE TOP 15 SPECIALIST DRUG DELIVERY
COMPANIES IN 1992 5.13
TABLE 6.1 DELIVERY SYSTEMS FOR BIOPHARMACEUTICALS 6.18
| |
